Sei Investments Co. Has $3.25 Million Holdings in Puma Biotechnology, Inc. $PBYI

Sei Investments Co. increased its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 18.2% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 508,182 shares of the biopharmaceutical company’s stock after acquiring an additional 78,257 shares during the period. Sei Investments Co.’s holdings in Puma Biotechnology were worth $3,247,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its stake in Puma Biotechnology by 7.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,436,106 shares of the biopharmaceutical company’s stock worth $9,175,000 after acquiring an additional 96,503 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its holdings in Puma Biotechnology by 35.3% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 1,120,329 shares of the biopharmaceutical company’s stock valued at $6,666,000 after purchasing an additional 292,108 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Puma Biotechnology by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 994,345 shares of the biopharmaceutical company’s stock valued at $5,917,000 after purchasing an additional 10,823 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Puma Biotechnology by 4,823,365.0% in the third quarter. Russell Investments Group Ltd. now owns 964,693 shares of the biopharmaceutical company’s stock valued at $5,123,000 after buying an additional 964,673 shares in the last quarter. Finally, State Street Corp grew its stake in Puma Biotechnology by 17.2% during the fourth quarter. State Street Corp now owns 877,077 shares of the biopharmaceutical company’s stock worth $5,219,000 after buying an additional 128,419 shares during the last quarter. 61.29% of the stock is currently owned by institutional investors.

Key Puma Biotechnology News

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Puma reported earnings of $0.19 per share, above the $0.04 consensus estimate, while revenue reached $56.5 million versus expectations of $53.0 million. Profitability included a 10.69% net margin and 20.30% return on equity. Puma Biotechnology Q2 2026 earnings results
• Positive Sentiment: Full-year 2026 revenue guidance was raised. Puma now expects revenue of $224 million to $231 million, above the approximately $222.5 million analyst consensus. Rising Nerlynx sales and planned milestones for the alisertib program provide additional potential catalysts. PBYI Q2 earnings and raised guidance
• Neutral Sentiment: Management’s outlook was mixed for the next quarter. Third-quarter revenue guidance of $56 million to $59 million is slightly below the $59.4 million consensus estimate, suggesting that near-term growth may be more modest despite the improved full-year outlook. Puma Biotech Q2 earnings and revenue results
• Negative Sentiment: TD Cowen remains cautious. The firm raised its price target from $5 to $6 but maintained a “hold” rating. The revised target still implies roughly 32.7% downside from the referenced $8.91 share price, potentially weighing on investor sentiment after the recent advance. TD Cowen raises Puma Biotechnology price target

Puma Biotechnology Price Performance

Shares of NASDAQ PBYI opened at $8.91 on Friday. Puma Biotechnology, Inc. has a fifty-two week low of $3.05 and a fifty-two week high of $9.40. The firm has a market capitalization of $453.52 million, a P/E ratio of 17.13 and a beta of 1.22. The company’s 50 day simple moving average is $7.80 and its 200 day simple moving average is $7.18.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.15. The firm had revenue of $56.50 million during the quarter, compared to analyst estimates of $53.00 million. Puma Biotechnology had a net margin of 11.50% and a return on equity of 21.34%. Sell-side analysts expect that Puma Biotechnology, Inc. will post 0.28 EPS for the current fiscal year.

Analysts Set New Price Targets

PBYI has been the subject of several recent analyst reports. TD Cowen raised their price objective on shares of Puma Biotechnology from $5.00 to $6.00 and gave the stock a “hold” rating in a report on Friday. Weiss Ratings lowered Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. Two research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.00.

Insider Buying and Selling at Puma Biotechnology

In other news, Director Jay M. Moyes sold 22,000 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $7.22, for a total transaction of $158,840.00. Following the completion of the transaction, the director directly owned 58,322 shares in the company, valued at approximately $421,084.84. The trade was a 27.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Alan H. Auerbach sold 44,058 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $8.26, for a total value of $363,919.08. Following the completion of the sale, the chief executive officer directly owned 7,261,671 shares of the company’s stock, valued at approximately $59,981,402.46. This trade represents a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 132,028 shares of company stock valued at $1,006,711 over the last quarter. 22.20% of the stock is owned by corporate insiders.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late?stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small?molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early?stage HER2-positive breast cancer.